Anthrax Treatment Engineered by Texas CHE Researchers Gains FDA Approval
/in News /by adminResearchers at The University of Texas at Austin, including Texas ChE’s Dr. George Georgiou and Dr. Jennifer Maynard, successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA). Part of the molecule was engineered at UT Austin before being licensed to New Jersey-based pharmaceutical company Elusys Therapeutics for further development. It will be sold under the name Anthim.
Popular
- George Georgiou, 2014 UT Austin Inventor of the YearMarch 31, 2014 - 12:44 AM
- Dr. Georgiou Elected to the National Academy of Invento...December 15, 2015 - 12:45 AM
- Fighting Lymphoma Cancer with Genomics and Supercomputi...March 31, 2016 - 12:45 AM
- Anthrax Treatment Engineered by Texas CHE Researchers Gains...April 4, 2016 - 12:47 AM
Recent
- Our Covid Research Featured on NIH Director’s Blo...May 18, 2021 - 4:40 PM
- The Institute a Member of the Nationwide NIH COVID-19 S...October 8, 2020 - 11:25 PM
- Drs. Ippolito and Lavinder featured in the Austin American...September 23, 2020 - 2:17 PM
- Institute Develops Antibody Test for COVID-19 That is Sensitive,...September 13, 2020 - 4:19 PM
Comments
Tags